

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RE APPLICATION OF:

Mantell et al.

EXAMINER: Patrick Lewis

SERIAL NO.: 09/590,585

Lhereby certify that this correspondence T UNIT: 1623 Is being deposited with the United States

FILED: June 8, 2000

Postal Service as First Class Mail in an

FOR: Purine Derivatives

envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on

Asst. Commissioner for Patents

Washington, DC 20231

this We day of Dovembe 20 0

Sir:

This is in response to the Office Action mailed October 8, 2002 in the subject patent application. The term for responding to this Office Action was set to expire one month from October 8, 2002, i.e., on November 8, 2002. Applicants have filed herewith a petition for a one month extension of time such that the term for responding to the Office Action expires on December 8, 2002. Accordingly, this response is being timely filed.

RESPONSE UNDER 35 U.S.C. §1.111 AND U.S.C. §1.21

-Amendments-

Please amend the application as follows:

In the Claims:

Amend Claims 4, 5, 8 - 10, 13, 18, 25 - 27, 29, 31 and 33:

RECEIVED

NOV 2.7 2002

TECH CENTER 1600/2000

(Amended)

A compound as claimed in claim 1 wherein R² is H.

5.

4.

(Amended)

A compound as claimed in claim 1 wherein A is C₁-C₄

alkylene.

8. (Amended) A compound as claimed in claim 1 wherein R³ is phenyl optionally substituted by C₁-C₆ alkyl, phenyl, C₁-C₆ alkoxy(C₁-C₆)alkyl, R⁴R⁴N(C₁-C₆)alkyl, halo(C₁-C₆)alkyl, fluoro(C₁-C₆)alkoxy, C₂-C₅ alkanoyl, halo, -OR⁴, cyano, -COOR⁴, C₃-C₈ cycloalkyl, -S(O)_mR⁵, -NR⁴R⁴, -SO₂NR⁴R⁴, -CONR⁴R⁴, -NR⁴COR⁵ or -NR⁴SO₂R⁵; or, when A is C₂-C₆ alkylene, R³ is -NR⁴R⁴ wherein R⁴ is H, C₁-C₆ alkyl, C₃-